18/05/2026
Kairos Pharma Ltd. (NYSE American: KAPA) announced its annual shareholder meeting will be held virtually on June 29, 2026, at 9 a.m. PDT. The clinical-stage biopharmaceutical company also disclosed a going concern explanatory paragraph in its 2025 annual report audit, as required by NYSE American regulations.
The Los Angeles-based oncology company is developing ENV-105, an antibody targeting CD105 to overcome drug resistance in cancer. The lead candidate is currently in Phase 2 trials for castrate-resistant prostate cancer and Phase 1 trials for non-small cell lung cancer. The company notes that ENV-105 has not yet received FDA approval.